Media stories about McKesson (NYSE:MCK) have been trending somewhat positive on Wednesday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. McKesson earned a coverage optimism score of 0.25 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.5461892744235 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- iOFFICE Launches HUMMINGBIRD App (consumerelectronicsnet.com)
- Mysterious McKesson, the Massive CA Health Care Conglomerate You’ve Never Heard Of (citywatchla.com)
- The biggest company in California that you haven’t heard about – OCRegister (ocregister.com)
- From drug pricing and ‘biosimilars’ to opioids and culture — a wrap and podcast from biotech’s big conference (feeds.bizjournals.com)
- William Barber II and the MLK Legacy of Church-Based Activism (nymag.com)
MCK has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $173.00 price target (down previously from $178.00) on shares of McKesson in a report on Wednesday, November 1st. ValuEngine cut McKesson from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Jefferies Group set a $165.00 price target on McKesson and gave the stock a “hold” rating in a report on Wednesday, October 18th. Evercore ISI assumed coverage on McKesson in a research report on Thursday, January 4th. They issued an “outperform” rating and a $179.00 target price on the stock. Finally, Zacks Investment Research raised McKesson from a “hold” rating to a “buy” rating and set a $177.00 target price on the stock in a research report on Tuesday, December 26th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the stock. McKesson presently has an average rating of “Hold” and an average price target of $174.64.
McKesson (NYSE:MCK) last issued its earnings results on Thursday, October 26th. The company reported $3.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.78 by $0.50. McKesson had a return on equity of 24.87% and a net margin of 2.24%. The firm had revenue of $52.06 billion for the quarter, compared to analyst estimates of $51.69 billion. During the same period last year, the company earned $2.94 earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. equities research analysts forecast that McKesson will post 12.23 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, January 2nd. Shareholders of record on Friday, December 1st were given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.79%. The ex-dividend date was Thursday, November 30th. McKesson’s dividend payout ratio is presently 6.44%.
In other McKesson news, Chairman John H. Hammergren sold 65,000 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $160.00, for a total value of $10,400,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.20% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://baseballnewssource.com/markets/mckesson-mck-earning-somewhat-positive-news-coverage-study-finds/1823750.html.
McKesson Company Profile
McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.